Results 201 to 210 of about 38,631 (238)
Some of the next articles are maybe not open access.
Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor
Expert Opinion on Drug Metabolism & Toxicology, 2005Erectile dysfunction (ED) is a widespread, age-related medical condition that affects > 50% of men aged 40 - 70 years. Pharmacotherapy with orally available phosphodiesterase 5 (PDE5) inhibitors offers a convenient and simple approach to treatment. Results of numerous clinical trials have demonstrated significant efficacy in restoring the ability to ...
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class
Urologic Clinics of North America, 2007With three effective and safe phosphodiesterase type 5 (PDE5) inhibitors, the clinician now has multiple choices in the treatment of patients who have erectile dysfunction of all severities and etiologies. Based on pharmacokinetics, pharmacodynamics, efficacy, and safety, each of these agents can be used.
openaire +2 more sources
Phosphodiesterase type 5 inhibitors and endothelial function
Current Sexual Health Reports, 2007Erectile dysfunction (ED) and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors (CRFs) and are longitudinal predictors of cardiovascular events. ED is associated with systemic endothelial cell activation/dysfunction independent from CRFs or from diffuse, unrecognized vascular damage.
Antonio Aversa, Roberto Bruzziches
openaire +1 more source
Vision Disorders and Phosphodiesterase Type 5 Inhibitors
Drug Safety, 2009Phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, vardenafil and tadalafil) have been in widespread use for the safe and effective treatment of erectile dysfunction (ED) for nearly a decade. During that time, a relatively small number of patients have experienced adverse visual events, including nonarteritic anterior ischaemic optic neuropathy ...
openaire +2 more sources
Chronic dosing of phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2008Ten years ago, the introduction of sildenafil citrate for the treatment of erectile dysfunction fundamentally changed the field of sexual medicine. The sexual indications, along with the pharmacologic characteristics of this drug, led to its approval for on-demand use.
openaire +1 more source
Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors
Vascular, 2013Thromboangiitis obliterans, or Buerger’s disease, is a non-atherosclerotic, segmental, inflammatory disease affecting the small- and medium-sized vessels of the distal extremities. Other than discontinuation of tobacco, there is no standard-of-care treatment. Although two randomized trials have demonstrated a role for intravenous iloprost, no oral drug
Aryeh M, Abeles +3 more
openaire +2 more sources
Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction
World Journal of Urology, 2005Erectile dysfunction (ED) affects the sexual lives of millions of men. The first-line oral pharmacotherapy for most ED patients is phosphodiesterase type-5 (PDE-5) inhibitors, of which three are available. Sildenafil is the most widely prescribed oral agent for ED and has a very satisfactory efficacy-safety profile in all patient categories.
BRIGANTI , ALBERTO +6 more
openaire +3 more sources
Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859
European Journal of Pharmacology, 2003We have characterized a novel, potent, and selective phosphodiesterase type 5 inhibitor, JNJ-10258859 ((R)-(-)-3-(2,3-dihydro-benzofuran-5-yl)-2-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-1,2,3,4-tetrahydro-pyrrolo[3,4-b]quinolin-9-one). Its inhibitory effects on phosphodiesterase 1-6 were determined using enzymes partially purified from human tissues.
Yuhong, Qiu +11 more
openaire +2 more sources
Optimizing response to phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2007Although using phosphodiesterase type 5 inhibitors to treat erectile dysfunction has been highly effective in clinical trials, many men do not achieve their desired goals and stop using the medication after a few attempts. The notion of optimizing response to pharmacologic interventions is relatively new to clinicians.
openaire +1 more source
[Erectile dysfunction and phosphodiesterase type 5 inhibitors].
Revue medicale de Bruxelles, 2003Erectile dysfunction affects 150 millions of men and its prevalence increases with age. The improvement of life expectancy will increase the worldwide prevalence to 300 million in 2025. Oral treatments are nowadays the first line therapy for the vast majority of people as they have a good reliability and tolerance and restore more spontaneity.
T, Roumeguère +2 more
openaire +1 more source